Table 3.
Summary of baseline demographic and laboratory covariates
| Covariate | PPK analyses index dataset (N = 1895) |
|---|---|
| Continuous | |
| Age, years, mean (SD) | 61.12 (11.12) |
| Body weight, kg, mean (SD) | 79.09 (19.28) |
| eGFR, mL/min/1.73 m2, mean (SD) | 78.49 (21.63) |
| Lactate dehydrogenase, U/L, mean (SD) | 350.85 (397.57) |
| Liver dysfunction groups, n (%) | |
| Missing | 18 (0.95) |
| Group A: normal | 1688 (89.08) |
| Group B: mild | 186 (9.82) |
| Group C: moderate | 2 (0.11) |
| Group D: severe | 1 (0.05) |
| Categorical | |
| Sex, n (%) | |
| Male | 1264 (66.7) |
| Female | 631 (33.3) |
| Race, n (%) | |
| White | 1685 (88.92) |
| African American/Black | 53 (2.8) |
| Asian | 122 (6.44) |
| Other | 33 (1.74) |
| Baseline performance status, n (%) | |
| 0 | 734 (38.73) |
| 1 | 1109 (58.52) |
| 2 | 52 (2.74) |
| Tumor type, n (%) | |
| MEL | 565 (29.82) |
| NSCLC | 659 (34.78) |
| RCC | 605 (31.93) |
| Other | 66 (3.48) |
eGFR, estimated glomerular filtration rate; MEL, melanoma; NSCLC, non‐small cell lung cancer; PPK, population pharmacokinetic; RCC, renal cell carcinoma; SD, standard deviation.